AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Karyopharm Therapeutics I... (KPTI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.66

-0.03 (-3.79%)

At close: Jan 28, 2025, 3:03 PM

undefined% (undefined)

Bid	0.66
Market Cap	83.32M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.05
PE Ratio (ttm)	-0.63
Forward PE	n/a
Analyst	Buy

Ask	0.66
Volume	448,479
Avg. Volume (20D)	1,043,223
Open	0.69
Previous Close	0.69
Day's Range	0.65 - 0.69
52-Week Range	0.58 - 1.95
Beta	undefined

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezo...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 6, 2013

Employees 325

Stock Exchange NASDAQ

Ticker Symbol KPTI

Website https://www.karyopharm.com

Analyst Forecast

According to 4 analyst ratings, the average rating for KPTI stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 657.23% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Karyopharm Therapeutics Inc. is scheduled to release its earnings on Feb 27, 2025, before market opens.
Analysts project revenue of $37.74M, reflecting a 11.83% YoY growth and earnings per share of -0.25, making a -30.56% decrease YoY.

Why Price Moved

2 months ago

+17.81%

Karyopharm Therapeutics shares are trading higher ... Unlock content with Pro Subscription

News

2 months ago · seekingalpha.com

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Elhan Webb - Senior Vice President, Investor Relations Richard Paulson - P...

2 months ago · zacks.com

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.30 per share a year ago.

2 months ago · zacks.com

Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.